• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

Cardiovascular product approval

Drug Safety Communication: Clarithromycin (Biaxin)- Potential Increased Risk of Heart Problems or Death in Patients With Heart Disease
February 25, 2018
Diseases & Health Tips

Clarithromycin (Biaxin)- Potential Increased Risk of Heart Problems or Death in Patients

FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. FDAs recommendation is based on a review of the results of a 10-year

More
Drug Safety Communication: Clarithromycin (Biaxin)- Potential Increased Risk of Heart Problems or Death in Patients With Heart Disease
Diseases & Health Tips

Clarithromycin (Biaxin)- Potential Increased Risk of Heart Problems or Death in Patients

February 25, 2018

FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased

More
  • Croda and Botanical Solution Inc. (BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production
  • Liquid Nitrogen Freezers Prove to be Game Changer for Pharma Industry
  • Breye Therapeutics Strengthens Management Team and Board
  • How Healthcare Professionals Benefit From Field Hospitals
  • Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop